Brain Cancer Clinical Trials

** UCI 10-10 **
Collecting Brain Tumor Specimens for Glioma Vaccine (Bota)

** UCI 12-18 **
Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments (Bota)

** EAF151 **
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma (Chow)

** UCI 17-13 **
VIGILANT: Registry to Collect Safety/Efficacy Info of Gliadel Wafer Used in Medical Practice (Carrillo)

** ACOSOG A221101 **
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme (Carrillo)

** SYMPTOM MANAGEMENT **

** mets-SPECIFIC **

** UCI 15-79 **
Phase II Open-label randomized study of radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 brain metastases from NSCLC (Carrillo)

** UCI 16-74 **
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

** CORRELATIVE **

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

05/18
** Brain Cancer Clinical Trials **

** UCI 16-55 **
Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

** NRG BN001 **
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (Kong)

** NRG BN003 **
Ph III Trial of observation versus irradiation for a gross totally resected grade II meningioma (Kong)

** UCI 17-115**
Phase II trial of AV-GBM-1 as an adjunctive therapy following primary surgery plus concurrent chemotherapy in patients with newly diagnosed glioblastoma (Bota)

** UCI 17-88**
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

** UCI 17-35 **
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

** ALLIANCE-A071601 **
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Carrillo)

** UCI 17-115 **
Ph II Study of Optune in Bevacizumab-Naïve Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

** ALLIANCE-S1609 **
*Some cohorts suspended*
Molecular Analysis for Therapy Choice – MATCH (Bota)

** UCI 16-22 **
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Efomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

** UCI 17-35 **
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

** ALLIANCE A071401 **
*SUSPENDED*
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Carrillo)

** UCI 13-14 **
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

** UCI 15-35 **
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

** UCI 16-56**
Ph II Trial of Optune in Bevacizumab-Naïve Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

** RTOG 3503 **
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

** **
Opening Soon

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu 05/18